About: Neuromuscular blockade management in the critically Ill patient

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neuromuscular blockade management in the critically Ill patient Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Neuromuscular blockade management in the critically Ill patient
Creator	Brull, Sorin Hernandez-Torres, Vivian Prielipp, Richard Ratzlaff, Robert Renew, J
topic	covid:c9ca0e43d432d73ce9c5493d6f7f0f463e2ea5f5#this
source	PMC
abstract	Neuromuscular blocking agents (NMBAs) can be an effective modality to address challenges that arise daily in the intensive care unit (ICU). These medications are often used to optimize mechanical ventilation, facilitate endotracheal intubation, stop overt shivering during therapeutic hypothermia following cardiac arrest, and may have a role in the management of life-threatening conditions such as elevated intracranial pressure and status asthmaticus (when deep sedation fails or is not tolerated). However, current NMBA use has decreased during the last decade due to concerns of potential adverse effects such as venous thrombosis, patient awareness during paralysis, development of critical illness myopathy, autonomic interactions, and even residual paralysis following cessation of NMBA use. It is therefore essential for clinicians to be familiar with evidence-based practices regarding appropriate NMBA use in order to select appropriate indications for their use and avoid complications. We believe that selecting the right NMBA, administering concomitant sedation and analgesic therapy, and using appropriate monitoring techniques mitigate these risks for critically ill patients. Therefore, we review the indications of NMBA use in the critical care setting and discuss the most appropriate use of NMBAs in the intensive care setting based on their structure, mechanism of action, side effects, and recognized clinical indications. Lastly, we highlight the available pharmacologic antagonists, strategies for sedation, newer neuromuscular monitoring techniques, and potential complications related to the use of NMBAs in the ICU setting.
has issue date	2020-05-24(xsd:dateTime)
bibo:doi	10.1186/s40560-020-00455-2
has license	cc-by
sha1sum (hex)	c9ca0e43d432d73ce9c5493d6f7f0f463e2ea5f5
schema:url	https://doi.org/10.1186/s40560-020-00455-2
resource representing a document's title	Neuromuscular blockade management in the critically Ill patient
has PubMed Central identifier	PMC7245849
schema:publication	J Intensive Care
resource representing a document's body	covid:c9ca0e43d432d73ce9c5493d6f7f0f463e2ea5f5#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/c9ca0e43d432d73ce9c5493d6f7f0f463e2ea5f5
is schema:about of	named entity 'tolerated' named entity 'based' named entity 'These' named entity 'evidence-based practices' named entity 'newer' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software